Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Sept 2015

Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Díez J J, Carrato A, García-Carbonero R

Abstract excerpt

BACKGROUND: The management of advanced neuroendocrine tumors (NETs) has recently changed. We assessed the activity of pazopanib after failure of other systemic treatments in advanced NETs. METHODS: This was a multicenter, open-label, phase II study evaluating pazopanib as a single agent in advanced NETs (PAZONET study). The clinical benefit rate (CBR) at 6 months was the primary end point. Translational...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Indazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplastic Cells, Circulating

Share to Neuroendocrine Tumors

Share to Pyrimidines

Share to Sulfonamides

Share to Vascular Endothelial Growth Factor Receptor-2

Share to Vascular Endothelial Growth Factor Receptor-3

Source

Identifiers

PMID: 26063633
DOI: 10.1093/annonc/mdv252

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).PMID 26063633Read ↗

Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?Semantic proximity Read ↗

Phase II trial of Pembrolizumab and Lenvatinib in Advanced Neuroendocrine Prostate Cancer (PLANE-PC)Semantic proximity Read ↗

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.Semantic proximity Read ↗

The evolving landscape of neuroendocrine tumors.Semantic proximity Read ↗

Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.Semantic proximity Read ↗

Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sitesSemantic proximity Read ↗

Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms.Semantic proximity Read ↗

Consensus Guideline for the Management of Peritoneal Metastases in Patients with Neuroendocrine NeoplasmsSemantic proximity Read ↗

Molecular pathogenesis of neuroendocrine tumors: implications for current and future therapeutic approaches.Semantic proximity Read ↗

BRAF V600E-mutated large cell neuroendocrine carcinoma responding to targeted therapy: a case report and review of the literature.Semantic proximity Read ↗

Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation.Semantic proximity Read ↗

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.